Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$6.14 – $6.77
Volume18,542
Market cap$137M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for MSLE.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for MSLE.
Recent news
Company coverage with links to the original publishers.
Satellos Bioscience announced Q3 2026 financial results with $53.0 million in cash runway through 2027. The company reported that BASECAMP Phase 2 pediatric DMD trial enrollment is complete with topline data expected in Q1 2027, using MRI-measured muscle fat fraction as the primary efficacy endpoint following FDA feedback. TRAVERSE Phase 2 trial in FSHD patients received regulatory clearance and is expected to begin enrollment in Q1 2027. The company reported a net loss of $11.2 million for Q3 2026.
Satellos Bioscience announced it has changed the primary efficacy endpoint in its BASECAMP Phase 2 clinical trial from dynamometry to MRI-measured fat fraction of the vastus lateralis, following FDA feedback. The change aims to support a potential accelerated approval pathway for forazapadin, its investigational treatment for Duchenne muscular dystrophy. Topline 12-week placebo-controlled data is expected in Q1 2027. Prior TRAILHEAD data in adults showed a 3.7 percentage-point reduction in muscle fat fraction, indicating improved muscle composition.
Satellos Bioscience announced that its management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026, and the Jefferies Global Healthcare Conference on November 18-19, 2026. The company will host a fireside chat and be available for one-on-one investor meetings at both events. Satellos is advancing its lead candidate forazapadin through Phase 2 clinical trials for Duchenne muscular dystrophy and plans to initiate a Phase 2 trial in facioscapulohumeral muscular dystrophy in Q4 2026.
Satellos Bioscience received FDA clearance for its IND application to test forazapadin in facioscapulohumeral muscular dystrophy (FSHD), expanding the drug candidate into a second degenerative muscle disease. The FSHD Canada Foundation will provide up to US$5 million in non-dilutive financing to support clinical development, with a Phase 2 study expected to begin in Q4 2026. Forazapadin is an AAK1 inhibitor designed to restore muscle repair and regeneration.
Satellos Bioscience Inc. held its Annual Meeting of Shareholders on June 17, 2026, with 55.3% shareholder participation. All nine director nominees were elected with strong support, with most receiving over 99% approval votes. PricewaterhouseCoopers LLP was re-appointed as the company's auditor. The clinical-stage biotech company continues advancing SAT-3247, its lead candidate for treating degenerative muscle diseases including DMD, with Phase II trials (BASECAMP in pediatrics and TRAILHEAD in adults) progressing on schedule.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.